CureSMA.org. Voice of the Patient Report. http://www.curesma.org/documents/advocacy-documents/sma-voice-of-the-patient.pdf. Accessed September 20, 2018.
Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015;12(2):290-302.
Bowerman M, Swoboda KJ, Michalski JP, et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol. 2012;72(2):256-268.
Wijngaarde CA, Blank AC, Stam M, et al. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12(1):67.
Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81(3):355-368.
Q4 & full year 2018: financial results and business update
[earnings report]. Biogen Inc.; January 29, 2019.
Accessed February 12, 2019.
Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.
CureSMA.org. #ShowYourRare and raise SMA awareness on World Rare Disease Day. http://www.curesma.org/news/rare-disease-day-2018.html. Accessed September 13, 2018.
Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27-32.
Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19(1):40-50.
Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6(8):1205-1214.
Park GH, Maeno-Hikichi Y, Awano T, Landmesser LT, Monani UR. Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci. 2010;30(36):12005-12019.
Wadman RI, Stam M, Jansen MD, et al. A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls. PLoS One. 2016;11(11):e0167087.
Lipnick SL, Agniel DM, Aggarwal R, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS One. 2019;14(3):e0213680.
CureSMA.org. New York to implement newborn screening for SMA October 1st. http://www.curesma.org/news/newyork-nbs-2018.html. Accessed January 10, 2019.
MDA.org. ONEVoice: Insights and Observations from a National Survey of Adults and Families Living with Neuromuscular Disease. https://www.mda.org/sites/default/files/2018/12/MDA_OneVoice_Whitepaper.pdf. Accessed February 28, 2019.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.